Skip to main content

Table 1 Demographic and disease related variables in 150 female patients with SLE

From: Prevalence and risk factors of vertebral compression fractures in female SLE patients

Demographic variables

Value

Patient age (years)

47 (20 to 82)

Weight (kg)

67 (43 to 96)

Height (cm)

166 (145 to 182)

BMI (kg/m2)

24.5 (17.2 to 35.3)

Exercise/week

0 (0 to 7)

Smoking status

 

   Nonsmoker n (%)

59 (39)

   Previous smoker n (%)

48 (32)

   Current smoker n (%)

43 (29)

   Years of smoking, current or previous

24 (0.5 to 48)

Menopausal status

 

   Premenopausal n (%)

67 (45)

   Postmenopasal n (%)

81 (55)

Dietary calcium intake (mg/day)

467 (0 to 1,510)

Disease variables

 

Disease duration (years)

11 (1 to 41)

SLEDAI-2K

5 (0 to 31)

DI

2 (0 to 11)

Haemoglobin (g/l)

131 (80 to 156)

ESR (mm/1 hr)

19 (2 to 125)

CRP (mg/l)

5 (3 to 79)

Creatinine (μmol/l)

88 (49 to 291)

Calcium, ionized (mmol/l)

1.22 (1.07 to 1.42)

Glucocortocosteroid (Prednisolone) user n (%)

78 (52)

   Prednisolone dose (mg)

5 (2.5 to 35)

Glucocorticosteroid (Prednisolone) ever user n (%)

129 (86)

   Cumulative Prednisolone dose (g)

11 (0.1 to 97.5)

Immunosuppressive drug user n (%)

80 (53)

Calcium and vitamin D n (%)

81 (54)

Bisphosphonates n (%)

21 (14)

Postmenopausal

 

   HRT n (%)

4 (5)

BMD lumbal spine (g/cm2) mean (SD)

1.12 (0.18)

BMD total hip (g/cm2) mean (SD)

0.93 (0.14)

BMD femur neck(g/cm2) mean (SD)

0.89 (0.14)

BMD radius total (g/cm2) mean (SD)

0.51 (0.08)

Patients with vertebral fracture n (%)

43 (29)

Vertebral fractures/patient

0 (0 to 11)

Sum of Genant's grading per patient

0 (0 to 22)

Patients with peripheral fracture n (%)

22 (14)

  1. Values are medians and (range) when not indicated otherwise.
  2. BMD, bone mineral density; BMI, body mass index; CRP, C-reactive protein; DI, Systemic Lupus International Collaborative Clinics/American Collage of Rheumatology Damage Index; ESR, erythrocyte sedimentation rat; HRT, hormone replacement therapy; SERM, selective estrogen receptor modulator; SLEDAI-2K, SLE disease activity index-2K.